{"id":60575,"date":"2026-03-23T15:49:18","date_gmt":"2026-03-23T07:49:18","guid":{"rendered":"https:\/\/flcube.com\/?p=60575"},"modified":"2026-03-23T15:49:19","modified_gmt":"2026-03-23T07:49:19","slug":"grand-pharma-wins-nmpa-approval-for-gpn01768-first-targeted-therapy-for-demodex-blepharitis-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=60575","title":{"rendered":"Grand Pharma Wins NMPA Approval for GPN01768 \u2013 First Targeted Therapy for Demodex Blepharitis in China"},"content":{"rendered":"\n<p><strong>Grand Pharmaceutical Group<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/0512:HKG\">HKG: 0512<\/a>) announced that its <strong>licensed\u2011in global innovative ophthalmic drug GPN01768 [TP\u201103, Lotilaner Ophthalmic Solution 0.25%]<\/strong> has received <strong>NMPA marketing approval<\/strong> for <strong>Demodex blepharitis<\/strong> \u2013 becoming the <strong>first targeted therapy<\/strong> for this common yet undertreated eyelid condition in China, acquired through a <strong>strategic licensing agreement with Tarsus Pharmaceuticals<\/strong> in March 2024.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>GPN01768 [TP\u201103, Lotilaner Ophthalmic Solution 0.25%]<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Grand Pharmaceutical Group (HKG: 0512)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Demodex blepharitis<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Selective, non\u2011competitive GABA\u2011Cl channel antagonist (insects\/arachnids)<\/td><\/tr><tr><td><strong>Origin<\/strong><\/td><td>Licensed from <strong>Tarsus Pharmaceuticals, Inc.<\/strong> (developer of TP\u201103)<\/td><\/tr><tr><td><strong>Licensing Date<\/strong><\/td><td>March 2024<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Greater China (Mainland China, Hong Kong, Macau, Taiwan) \u2013 <strong>exclusive rights<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-mechanism-of-action\">Product Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>Lotilaner<\/strong> \u2013 <strong>selective GABA\u2011gated chloride (GABA\u2011Cl) channel antagonist<\/strong><\/li>\n\n\n\n<li><strong>Target Organism:<\/strong> <strong>Demodex mites<\/strong> (parasitic arachnids inhabiting eyelid margins)<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong><\/li>\n\n\n\n<li>Selective inhibition of <strong>GABA\u2011Cl channels within Demodex mites<\/strong><\/li>\n\n\n\n<li>Induces <strong>paralysis and death<\/strong> of mites<\/li>\n\n\n\n<li><strong>Non\u2011competitive antagonism<\/strong> \u2013 sustained efficacy vs. competitive inhibitors<\/li>\n\n\n\n<li><strong>Formulation:<\/strong> <strong>0.25% ophthalmic solution<\/strong> \u2013 topical eyelid administration<\/li>\n\n\n\n<li><strong>Clinical Advantage:<\/strong> <strong>Targeted anti\u2011parasitic therapy<\/strong> vs. traditional off\u2011label treatments (tea tree oil, lid hygiene, antibiotics)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-licensing-partnership-structure\">Licensing Partnership Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dimension<\/th><th>Tarsus Pharmaceuticals<\/th><th>Grand Pharmaceutical Group<\/th><\/tr><\/thead><tbody><tr><td><strong>Role<\/strong><\/td><td>Origin asset developer (TP\u201103)<\/td><td>Greater China licensee<\/td><\/tr><tr><td><strong>Rights Granted<\/strong><\/td><td>\u2013<\/td><td><strong>Exclusive<\/strong> development, manufacturing, commercialization (Greater China)<\/td><\/tr><tr><td><strong>Deal Timing<\/strong><\/td><td>\u2013<\/td><td>March 2024 strategic licensing agreement<\/td><\/tr><tr><td><strong>Commercial Responsibility<\/strong><\/td><td>US and ex\u2011Greater China markets<\/td><td>China market launch and distribution<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-strategic-positioning\">Market Context &amp; Strategic Positioning<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dimension<\/th><th>Demodex Blepharitis Landscape<\/th><th>GPN01768 Position<\/th><\/tr><\/thead><tbody><tr><td><strong>Disease Prevalence<\/strong><\/td><td><strong>~25\u201130% of adults<\/strong> have Demodex blepharitis; often misdiagnosed as dry eye or allergic conjunctivitis<\/td><td>First <strong>etiologic treatment<\/strong> addressing root cause (mite eradication)<\/td><\/tr><tr><td><strong>Current Standard of Care<\/strong><\/td><td>Warm compresses, lid scrubs, tea tree oil (off\u2011label), topical antibiotics (ineffective against mites)<\/td><td><strong>First FDA\u2011approved<\/strong> (US 2023) and <strong>first NMPA\u2011approved<\/strong> targeted therapy<\/td><\/tr><tr><td><strong>Clinical Unmet Need<\/strong><\/td><td>Chronic, recurrent condition; significant quality\u2011of\u2011life impact (ocular irritation, cosmetic concerns); no approved pharmacotherapy<\/td><td>Single\u2011agent mite eradication with durable remission potential<\/td><\/tr><tr><td><strong>China Market Opportunity<\/strong><\/td><td>Estimated <strong>15\u201120 million<\/strong> affected adults; ophthalmology clinic volume high<\/td><td>First\u2011mover advantage in targeted blepharitis therapy; premium pricing vs. generic alternatives<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ophthalmic Market Dynamics:<\/strong> China ophthalmic pharmaceutical market <strong>RMB12\u201115 billion<\/strong> annually; dry eye and blepharitis segments growing <strong>10\u201115% CAGR<\/strong> driven by aging, digital screen exposure, and diagnostic awareness; GPN01768 addresses <strong>specific etiologic niche<\/strong> vs. crowded artificial tears and anti\u2011inflammatory segments.<\/li>\n\n\n\n<li><strong>Grand Pharma Portfolio Strategy:<\/strong> GPN01768 adds <strong>innovative ophthalmology asset<\/strong> to Grand Pharma&#8217;s established cardiovascular and oncology franchises; licensing model (vs. internal R&amp;D) reduces development risk and accelerates market entry; Tarsus partnership provides <strong>technology transfer and manufacturing support<\/strong>.<\/li>\n\n\n\n<li><strong>Commercial Launch Trajectory:<\/strong> NMPA approval enables <strong>H2 2026 China launch<\/strong>; hospital\u2011based ophthalmology and optometry channels primary target; estimated <strong>RMB200\u2011300 million<\/strong> annual peak sales (2028\u20112030) assuming 5\u20118% market penetration in diagnosed Demodex blepharitis population; Hong Kong\/Macau\/Taiwan registration to follow Mainland China.<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> First\u2011in\u2011class GABA\u2011Cl mechanism vs. traditional anti\u2011parasitics (ivermectin, metronidazole) with limited ocular safety data; topical ophthalmic formulation (vs. oral\/systemic) minimizes systemic exposure; potential for <strong>label expansion<\/strong> to Demodex\u2011associated rosacea, meibomian gland dysfunction.<\/li>\n\n\n\n<li><strong>Global Market Validation:<\/strong> US FDA approval (July 2023) and NMPA approval validate <strong>transregional regulatory strategy<\/strong>; Tarsus retains US commercialization rights (Xdemvy brand); Grand Pharma&#8217;s China success may support <strong>ex\u2011Greater Asia partnership discussions<\/strong> for Japan, Korea, Southeast Asia markets.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding commercialization timelines, market penetration expectations, and partnership expansion potential for GPN01768. Actual results may differ due to reimbursement negotiations, physician adoption rates, and competitive dynamics in the ophthalmic therapeutics market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Grand Pharmaceutical Group (HKG: 0512) announced that its licensed\u2011in global innovative ophthalmic drug GPN01768 [TP\u201103,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":60576,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[683,1184,44,15],"class_list":["post-60575","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-grand-pharmaceutical","tag-hkg-0512","tag-ophthalmology","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Grand Pharma Wins NMPA Approval for GPN01768 \u2013 First Targeted Therapy for Demodex Blepharitis in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Grand Pharmaceutical Group (HKG: 0512) announced that its licensed\u2011in global innovative ophthalmic drug GPN01768 [TP\u201103, Lotilaner Ophthalmic Solution 0.25%] has received NMPA marketing approval for Demodex blepharitis \u2013 becoming the first targeted therapy for this common yet undertreated eyelid condition in China, acquired through a strategic licensing agreement with Tarsus Pharmaceuticals in March 2024.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=60575\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Grand Pharma Wins NMPA Approval for GPN01768 \u2013 First Targeted Therapy for Demodex Blepharitis in China\" \/>\n<meta property=\"og:description\" content=\"Grand Pharmaceutical Group (HKG: 0512) announced that its licensed\u2011in global innovative ophthalmic drug GPN01768 [TP\u201103, Lotilaner Ophthalmic Solution 0.25%] has received NMPA marketing approval for Demodex blepharitis \u2013 becoming the first targeted therapy for this common yet undertreated eyelid condition in China, acquired through a strategic licensing agreement with Tarsus Pharmaceuticals in March 2024.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=60575\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-23T07:49:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-23T07:49:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2305.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60575#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60575\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Grand Pharma Wins NMPA Approval for GPN01768 \u2013 First Targeted Therapy for Demodex Blepharitis in China\",\"datePublished\":\"2026-03-23T07:49:18+00:00\",\"dateModified\":\"2026-03-23T07:49:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60575\"},\"wordCount\":592,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60575#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2305.webp\",\"keywords\":[\"Grand Pharmaceutical\",\"HKG: 0512\",\"Ophthalmology\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60575#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60575\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=60575\",\"name\":\"Grand Pharma Wins NMPA Approval for GPN01768 \u2013 First Targeted Therapy for Demodex Blepharitis in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60575#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60575#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2305.webp\",\"datePublished\":\"2026-03-23T07:49:18+00:00\",\"dateModified\":\"2026-03-23T07:49:19+00:00\",\"description\":\"Grand Pharmaceutical Group (HKG: 0512) announced that its licensed\u2011in global innovative ophthalmic drug GPN01768 [TP\u201103, Lotilaner Ophthalmic Solution 0.25%] has received NMPA marketing approval for Demodex blepharitis \u2013 becoming the first targeted therapy for this common yet undertreated eyelid condition in China, acquired through a strategic licensing agreement with Tarsus Pharmaceuticals in March 2024.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60575#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60575\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60575#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2305.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2305.webp\",\"width\":1080,\"height\":608,\"caption\":\"Grand Pharma Wins NMPA Approval for GPN01768 \u2013 First Targeted Therapy for Demodex Blepharitis in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60575#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Grand Pharma Wins NMPA Approval for GPN01768 \u2013 First Targeted Therapy for Demodex Blepharitis in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Grand Pharma Wins NMPA Approval for GPN01768 \u2013 First Targeted Therapy for Demodex Blepharitis in China - Insight, China&#039;s Pharmaceutical Industry","description":"Grand Pharmaceutical Group (HKG: 0512) announced that its licensed\u2011in global innovative ophthalmic drug GPN01768 [TP\u201103, Lotilaner Ophthalmic Solution 0.25%] has received NMPA marketing approval for Demodex blepharitis \u2013 becoming the first targeted therapy for this common yet undertreated eyelid condition in China, acquired through a strategic licensing agreement with Tarsus Pharmaceuticals in March 2024.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=60575","og_locale":"en_US","og_type":"article","og_title":"Grand Pharma Wins NMPA Approval for GPN01768 \u2013 First Targeted Therapy for Demodex Blepharitis in China","og_description":"Grand Pharmaceutical Group (HKG: 0512) announced that its licensed\u2011in global innovative ophthalmic drug GPN01768 [TP\u201103, Lotilaner Ophthalmic Solution 0.25%] has received NMPA marketing approval for Demodex blepharitis \u2013 becoming the first targeted therapy for this common yet undertreated eyelid condition in China, acquired through a strategic licensing agreement with Tarsus Pharmaceuticals in March 2024.","og_url":"https:\/\/flcube.com\/?p=60575","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-23T07:49:18+00:00","article_modified_time":"2026-03-23T07:49:19+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2305.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=60575#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=60575"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Grand Pharma Wins NMPA Approval for GPN01768 \u2013 First Targeted Therapy for Demodex Blepharitis in China","datePublished":"2026-03-23T07:49:18+00:00","dateModified":"2026-03-23T07:49:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=60575"},"wordCount":592,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=60575#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2305.webp","keywords":["Grand Pharmaceutical","HKG: 0512","Ophthalmology","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=60575#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=60575","url":"https:\/\/flcube.com\/?p=60575","name":"Grand Pharma Wins NMPA Approval for GPN01768 \u2013 First Targeted Therapy for Demodex Blepharitis in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=60575#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=60575#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2305.webp","datePublished":"2026-03-23T07:49:18+00:00","dateModified":"2026-03-23T07:49:19+00:00","description":"Grand Pharmaceutical Group (HKG: 0512) announced that its licensed\u2011in global innovative ophthalmic drug GPN01768 [TP\u201103, Lotilaner Ophthalmic Solution 0.25%] has received NMPA marketing approval for Demodex blepharitis \u2013 becoming the first targeted therapy for this common yet undertreated eyelid condition in China, acquired through a strategic licensing agreement with Tarsus Pharmaceuticals in March 2024.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=60575#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=60575"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=60575#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2305.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2305.webp","width":1080,"height":608,"caption":"Grand Pharma Wins NMPA Approval for GPN01768 \u2013 First Targeted Therapy for Demodex Blepharitis in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=60575#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Grand Pharma Wins NMPA Approval for GPN01768 \u2013 First Targeted Therapy for Demodex Blepharitis in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2305.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60575","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=60575"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60575\/revisions"}],"predecessor-version":[{"id":60577,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60575\/revisions\/60577"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/60576"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=60575"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=60575"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=60575"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}